10/06/2025 - General information
The Spanish Society of Neurology has awarded the scientific career of the coordinator of the Multiple Sclerosis Unit at Hospital del Mar and the coordinator of the Neuroimmunology Research Group at its research institute. Dr. José Enrique Martínez received the 'Premio SEN Esclerosis Múltiple' on June 4th, during the Institutional Ceremony of the Spanish Society of Neurology, recognizing his scientific work in this field. These awards represent the SEN's recognition of individuals or entities that have contributed to the development of neurology.
Més informació "SEN Multiple Sclerosis Award for Dr. José Enrique Martínez"
06/06/25 - Press release
Having high blood levels of a type of molecule, spermidine, before surgery increases the risk of tumor recurrence after surgery by 4.7 times. This risk decreases if spermidine levels in the patient's blood drop after surgery. The study is published in the Annals of Surgery journal and opens the door to determining which individuals are at higher risk, either before entering the operating room or just afterward, in order to offer them complementary or specific treatment.
27/05/2025 - Press release
A joint project between the three research institutions has been selected for funding by the XPRIZE Foundation of the United States. It will receive $250,000 to demonstrate that it is possible to extend human healthy lifespan. The VITA project proposes combining two existing molecules and a multimodal lifestyle intervention to extend quality of life during aging. The team formed by the three institutions now has one year to provide the first preliminary results and move on to a new stage of the awards, where the efficacy of the proposed new therapy will be assessed.
20/05/2025 - Press release
A study from the Hospital del Mar, the Hospital del Mar Research Institute, and the Reference Laboratory of Catalonia validates the effectiveness of combining a molecule, apotransferrin, with existing antibiotics to treat the antibiotic-resistant bacteria Pseudomonas aeruginosa. The research, published in the International Journal of Antimicrobial Agents, opens the door to a new strategy for tackling the problem of antibiotic-resistant bacteria by preventing them from accessing the iron they need to complete their life cycle. The new drug combination enhances the ability of antibiotics. Additionally, apotransferrin is a drug already used in other diseases, which could facilitate its use in bacterial infections.
16/05/2025 - Press release
Researchers from the Stem Cells and Cancer team at the Josep Carreras Leukaemia Research Institute and the Hospital del Mar Research Institute have developed a method to confidently produce blood cell precursors from stem cells in mice, by activating a set of seven key genes in the laboratory. The team, led by Dr. Anna Bigas, takes a step forward towards the production of precursor cells able to restore the bone marrow of blood cancer patients, in a successful example of regenerative medicine.
08/05/2025 - Institutional news
The Blood and Tissue Bank (BST) and the Hospital del Mar Research Institute have signed a collaboration agreement to combine efforts and resources, creating synergies and working closely together in the field of research, especially in advanced therapies. The goal is to facilitate their clinical application to accelerate their impact on patients. The agreement, defined as the Joint Research Program in Substances of Human Origin (SoHO) and Advanced Therapies, will have an initial duration of 4 years and will be led by Luís Álvarez-Vallina, the new Research Director at the Blood and Tissue Bank.
25/04/2025 - General information
Dr. Anna Bigas, coordinator of the Stem Cells and Cancer Research Group at the Hospital del Mar Research Institute, has been appointed Visiting Professor at Åbo Akademi University in Turku, Finland. Her appointment aims to strengthen the InFLAMES project, a joint initiative between Åbo Akademi and the University of Turku. Dr. Bigas focuses part of her research on generating blood stem cells in the lab, as well as understanding chemotherapy resistance mechanisms in acute leukemias. With her incorporation into Åbo Akademi University, the institution seeks to boost its research capabilities in the field of hematopoietic stem cells and blood-related disorders.
Més informació "Finnish Åbo Akademi University appoints Dr. Anna Bigas as Visiting Professor"
22/04/2025 - Covid-19
A study led by the Hospital del Mar Research Institute, in collaboration with the Caldes de Montbui City Council, has validated the use of thermal waters to reduce some symptoms in people affected by long COVID. Balneotherapy helped improve pain and fatigue, with benefits that persisted after treatment ended. Improvements were also observed in sleep quality and anxiety, although these did not last over time. People with long COVID who underwent a one-month thermal water treatment program were twice as likely to improve their symptoms compared to those who did not receive the treatment.
Més informació "Balneotherapy Improves Various Symptoms of Long COVID"
15/04/2025 - Press release
A study by researchers from the Hospital del Mar Research Institute, IIBB-CSIC-IDIBAPS, Mayo Clinic, IBYME (CONICET), and CaixaResearch Institute demonstrates the role of the Galectin-1 protein in the nucleus of the cells surrounding the tumor-fibroblasts-contributing to their activation. Activated fibroblasts promote tumor growth and spread, while also conferring resistance to treatments. This may be one of the reasons behind the high aggressiveness of pancreatic cancer, which has a five-year survival rate of only 10%. The study's findings open the door to new therapeutic strategies against this type of cancer, focusing on the possibility of inhibiting this protein within the cells that surround and protect the tumor.
Més informació "Key to the high aggressiveness of pancreatic cancer identified"
11/04/25 - Institutional news
Dr. Jenniffer Linares, a researcher with the Colorectal Cancer Precision Medicine Research Group at the Hospital del Mar Research Institute, has received the CRIS Program for Translational Medical Talent, awarded by the CRIS Against Cancer Foundation. A total of 11 million euros in funding has been granted through the CRIS Research Programs 2024, with the aim of promoting cancer research that places the patient at the center of scientific advancement. The awarded project, "Uncovering the Clinical Impact of Stromal-Derived Mechanisms of Resistance to Anti-EGFR Therapy in Colorectal Cancer," seeks to understand the mechanisms of resistance to anti-EGFR therapies derived from the tumor microenvironment in patients with RAS wild-type metastatic colorectal cancer. The goal is to identify predictive markers and develop new therapeutic strategies to overcome these mechanisms. The project will receive funding of 400,000 euros.
Més informació "CRIS Against Cancer Awards Dr. Jenniffer Linares"
Servei de Comunicació:
Marta Calsina Freixas(ELIMINAR)
Tel:
(+34) 93 316 06 80
Doctor Aiguader, 88
08226 Barcelona
© Institut Hospital del Mar
d'Investigacions MèdiquesLegal Notice and Privacy Policy | Cookie Policy | Site Index | Accessibility | Find Us | Contact
